$ALLO

$1.21 -$0.04 (3.2%) Close

$ALLO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 345.5M shares outstanding

Who owns ALLO?

By type of holder

Institutions 90.5% Insiders 3.7% Everyone else 5.9%

Concentration Top 10 holders own 50.1%

BlackRock, Inc. 8.7% · Frazier Life Sciences Management, L.P. 6.5%

Institutional ownership

90.5%

+37.2 pts vs last qtr

Institutional holders

208

-1 vs last qtr

Net shares bought

+128.4M

by institutions in Q2 2026

New / sold out

32 / 33

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Frazier Life Sciences Management, L.P. +18.7M
Sio Capital Management, LLC NEW +13.3M

Biggest sellers in Q2 2026

MPM Bioimpact LLC SOLD OUT −2.2M
Nuveen, LLC −1.7M

Who is planning to sell?

Notices of proposed sale, last 12 months

$952K

15 notices from 12 people

Shares covered

512.8K

0.15% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

David Chang Officer $439K
Chang David D Officer $118K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2019–FY2025

+118.3%

+13.90% a year

Each share's claim on the business

−54.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $431M

over 7 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years50% 3–5 years10% 1–3 years22% Under 1 year18%

Quarterly turnover

41.2%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting ALLO on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
B BlackRock, Inc.	30.1M	8.73%	+11.1M (+57.9%)	≤2021	0.0%
Shares held by quarter Peak holding30.1M (Q2'26) Change over 8 quarters+12.4M Share of the company8.730% BlackRock, Inc.'s full portfolio →
FL Frazier Life Sciences Management, L.P.	22.4M	6.50%	+18.7M (+491.2%)	2024	1.0%
Shares held by quarter Peak holding22.4M (Q2'26) Change over 8 quarters+19.6M Share of the company6.500% Frazier Life Sciences Management, L.P.'s full portfolio →

BlackRock, Inc.

30.1M

% of company

8.73%

Change vs last qtr

+11.1M (+57.9%)

Held since

≤2021

Frazier Life Sciences Management, L.P.

22.4M

% of company

6.50%

Change vs last qtr

+18.7M (+491.2%)

Held since

2024

28 more super investors behind a free account

See every manager holding Allogene Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ALLO on Form N-PORT; together they hold 28.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$25.3M	12.1M	3.51%	0.24%	June 30, 2026
SB Select Biotechnology Portfolio Fidelity Select Portfolios	$20.1M	10.0M	2.91%	0.32%	August 31, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$25.3M

% of company

3.51%

% of the fund

0.24%

As of

June 30, 2026

Select Biotechnology Portfolio

Fidelity Select Portfolios

Position value

$20.1M

% of company

2.91%

% of the fund

0.32%

As of

August 31, 2026

23 more funds behind a free account

See every fund holding Allogene Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CD Chang David D Insider	6.4M	1.84%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.840% Chang David D's insider activity →
BA Belldegrun Arie Insider	2.8M	0.80%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.800% Belldegrun Arie's insider activity →

Chang David D

Insider

6.4M

% of company

1.84%

Change vs last qtr

—

Held since

—

Belldegrun Arie

Insider

2.8M

% of company

0.80%

Change vs last qtr

—

Held since

—

9 more holders behind a free account

See every insider and 5%+ holder of Allogene Therapeutics, Inc..

Comments